ALK and non-small cell lung carcinoma: emphasized the efficacy of ensartinib in Chinese patients with advanced ALK NSCLC and demonstrated that ensartinib showed good clinical activity and an acceptable safety profile in Chinese patients with ALK-positive NSCLC through safety, tolerability, pharmacokinetics, efficacy, and possible pharmacodynamic biomarkers which boosted the approval of ensartinib for the treatment of ALK-positive NSCLC patients in China (13).